Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGynecological OncologyradiotherapyDiseaseVulvar CarcinomaSubgroupICD10C51.9MeSHVulvaSequenceChemotherapyChemo-substanceCisplatinGemcitabineChemo-substanceCisplatinGemcitabineChemo-substanceCisplatinGemcitabineChemo-substanceCisplatinGemcitabineNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePotassium chlorideNo. Substances6Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentioncurativeRisksAnemia Hb below 8g/dlDiarrheaEmetogenicity (MASCC/ESMO)InfectionsLeukopeniaNeutropeniaRashThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorHorowitz NS Moore DHDiseaseVulvakarzinom, T2/T3, N0-3, M0, für eine radikale Vulvektomie nicht geeignet, keine VortherapieVulvakarzinom, T3/T4, N0-3, M0, für eine radikale Vulvektomie nicht geeignet, keine VortherapieOriginBrigham and Women's Hospital, Dana-Farber Cancer Institute, GOG Study 279Gynecologic Oncology of Indiana, Indianapolis, USA, GOG studyProtocols in Revision 2 protocols foundProtocols under revision.Cisplatin 40 / Radiatio, Vulvar Carcinoma (PID2116 V1.0)Gemcitabine 50 / Cisplatin 40 / Radiation, vulvar carcinoma (PID2603 V1.0)
